EAT is up +49.38%% since April’24 pick View All Top Buy Picks
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of VCYT
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Evaluation of Veracyte stock downgraded after the last trading session.
(Updated on Jun 28, 2024)

Sell candidate since Jun 28, 2024 PDF

The Veracyte stock price fell by -1.46% on the last day (Friday, 28th Jun 2024) from $21.99 to $21.67. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 4.69% from a day low at $21.13 to a day high of $22.12. The price has been going up and down for this period, and there has been a -0.55% loss for the last 2 weeks. Volume has increased on the last day by 760 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $30.60 million.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 9.88% during the next 3 months and, with a 90% probability hold a price between $22.68 and $27.05 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

VCYT Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Veracyte stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $22.30 and $21.74. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, May 15, 2024, and so far it has fallen -7.98%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Veracyte stock

Veracyte finds support from accumulated volume at $21.41 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.99 between high and low, or 4.69%. For the last week, the stock has had daily average volatility of 3.32%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (VCYT) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect Veracyte to open at $21.64, and during the day (based on 14 day Average True Range), to move between $20.84 and $22.50, which gives a possible trading interval of +/-$0.83 (+/-3.83%) up or down from last closing price. If Veracyte takes out the full calculated possible swing range there will be an estimated 7.66% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $21.41 (1.20%) than the resistance at $22.50 (3.83%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Veracyte stock A Buy?

The Veracyte stock holds several negative signals and despite the positive trend, we believe Veracyte will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Sell candidate.

Current score: -5.004 Strong Sell Candidate Downgraded

Predicted Opening Price for Veracyte of Monday, July 1, 2024

Fair opening price July 1, 2024 Current price
$21.64 ( 0.138%) $21.67

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for VCYT

Fibonacci Support & Resistance Levels

Level Price
R3 22.63 4.43%
R2 22.25 2.68%
R1 22.02 1.61%
Price 21.67
S1 21.26 -1.88%
S2 21.03 -2.96%
S3 20.65 -4.71%

Accumulated Volume Support & Resistance Levels

Level Price
R3 23.02 6.23%
R2 22.54 4.01%
R1 22.50 3.83%
Price 21.67
S1 21.41 -1.20%
S2 20.63 -4.80%
S3 20.12 -7.15%

FAQ

What is the symbol for Veracyte Stock and on which exchange is it traded?
The symbol for Veracyte is VCYT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Veracyte Stock?
The Veracyte stock holds several negative signals and despite the positive trend, we believe Veracyte will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Sell candidate.

How to buy Veracyte Stock?
Veracyte Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Veracyte Stock.

What's the current price of Veracyte Stock?
As of the end of day on the Jun 28, 2024, the price of an Veracyte (VCYT) share was $21.67.

What is the 52-week high and low for Veracyte Stock?
The 52-week high for Veracyte Stock is $30.52 and the 52-week low is $18.61.

What is the market capitalization of Veracyte Stock?
As of the Jun 28, 2024, the market capitalization of Veracyte is 1.657B.

When is the next earnings date for Veracyte?
The upcoming earnings date for Veracyte is Aug 13, 2024.
Click to get the best stock tips daily for free!

About Veracyte

Veracyte Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ... VCYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT